Compare ResMed Inc. (RMD) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Schwab US Large Cap Growth ETF — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Schwab US Large Cap Growth ETF trades at $36.75 (market cap $65.01B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 2× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| RMD | SCHG | |
|---|---|---|
Market Cap | $31.89B | $65.01B |
Volume | 618,314 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $277.88 | $36.93 |
52-Week Low | $182.82 | $28.10 |
Typical Hold Time | 51 Days | 50 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
SCHG trades at $36.74, down 0.35% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional interest despite a recent position reduction by Corient Private Wealth. Recent news highlights SCHG's low 0.03% expense ratio and its focus on large-cap growth stocks, though concentration in top holdings remains a structural consideration.
The outlook for SCHG remains positive given its growth orientation and cost efficiency, though investors should monitor concentration risks in top holdings. Market leadership in growth sectors and competitive fees support long-term potential, while sensitivity to tech sector volatility presents the primary near-term risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
